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Summary Pharmacokinetics of the cis-platin analog ethylenediaminemalonatoplatinum(II) (JM-40) was
studied in 28 cycles of 19 patients during the phase I study of this drug. The drug was administered
intravenously by short-term (10-60min) infusion. Doses ranged from 20 to 1,200 mgm-2. JM-40 was
determined in plasma ultrafiltrate and urine by HPLC. Platinum (Pt) concentrations were determined in
plasma, plasma ultrafiltrate, urine and red blood cells by atomic absorption spectrometry up to 5 days after
administration of the drug. Ultrafilterable Pt could be determined up to 45 days after the infusion in one
patient sampled over such a long period. Pharmacokinetics of JM-40 showed a linear behaviour. The final
half-life of total Pt in plasma was 4.1 +0.9 days. The disposition of JM-40 was similar to that of
ultrafilterable Pt in respect to tl, (10 and 13min), tq (44 and 57min), volumes of distribution V, (11 and 121)
and Vs, (17 and 201), systemic clearance (256 and 223mlmin-1), renal clearance (69 and 73 mlmin-1) and
metabolic clearance (183 and 154mlmin-1). During the first 6h 27+9% of the administered dose was
excreted as JM-40. Cumulative platinum excretion in the urine amounted to 29+ 13%, 42+ 14% and
60+13% over the first 6h, 24h and 5 days, respectively. The uptake of platinum in red blood cells was
limited, comprising only 0.24+0.12% of the administered dose. Although JM-40 and carboplatin are
structurally closely related, pharmocokinetics and toxicity of JM-40 were more similar to cis-platin than to
carboplatin.
Ethylenediaminemalonatoplatinum(II) (JM-40, Figure 1) is
one of the second generation platinum complexes developed
with the aim to achieve a better therapeutic index than that
of the antitumour drug cis-diammine-dichloroplatinum(II)
(cis-platin) (Cleare et al., 1978). JM-40 was selected for
clinical evaluation on the basis of comparable activity (Rose
& Bradner 1984; Boven et al., 1985) and a favorable toxicity
profile (Schurig et al., 1984; Lelieveld et al., 1984) compared
to cis-platin in preclinical studies. In particular the low
emetogenic potential as determined in the ferret (Schurig et
al., 1984) and the limited nephrotoxicity observed in dogs
(Lelieveld et al., 1984) were reasons to conduct a phase I
trial. In this trial the maximum tolerable dose was reached at
1,200 mg m-2 (Winograd et al., 1986). Nephrotoxicity,
nausea and vomiting were dose-limiting toxicities.
Investigation of the pharmacokinetics during phase I
clinical trials is important because it may help to design an
optimal therapeutic regimen in phase II trials (Kovach,
1983). In the case of an analogue, pharmacokinetics can be
compared with that of the parent compound. Furthermore,
when preclinical information on animal pharmacokinetics is
available human pharmacokinetics at low doses of the phase
I trial may aid in escalating the dose as quickly and safely as
possible (Collins et al., 1986, Van Hennik et al. 1987). Thus,
clinical pharmacokinetics of JM-40 and platinum were
investigated in plasma, plasma ultrafiltrate, urine and red
blood cells.
Figure 1 Structural
platinum(II) (JM-40).
formula of ethylenediaminemalonato-
Patients and methods
Patients and materials
Pharmacokinetic studies were performed in 19 patients who
received 28 cycles of JM-40 within a dose range of 20-
1,200mgm-2. The median age of the patients (6 females, 13
males) was 57 yrs (range 37-74yrs). All patients had a
normal liver function. Renal function was decreased
(creatinine clearance <60mlmin-1) at the start of only 3
treatment cycles. Six patients had previously received other
platinum compounds (cis-platin, spiroplatin).
JM-40 was supplied by Johnson Matthey, Reading,
Berkshire, UK. It was formulated as an aqueous solution
(5 mgml -1) (T.J., Schoemaker, Slotervaart Hospital,
Amsterdam, The Netherlands) and diluted 1: 1 in 10%
glucose prior to administration. The solution was given i.v.
with an infusion time (T) of 10min up to a dose of
300 mg m-2. T increased to 60min because of increasing
volumes of the solubilized drug at higher dose levels.
Sampling and analysis
Blood samples (5ml) were collected in heparinized tubes
prior to administration of JM-40, at the end of the infusion
and at 10, 20, 30, 60, 90, 120, 150, 180, 210, 240, 360, 480,
1,220, 1,440min as well as 2, 3, 4, and 5 days thereafter.
Samples were processed immediately after collection. Blood
was centrifuged and 2 portions of I ml plasma were ultrafil-
trated in the MPS-I micropartition system provided with
YMT filters (cut-off 30,000 dalton, Amicon, Oosterhout, The
Netherlands) (Van der Vijgh et al., 1986). Red blood cells
(RBCs) were washed twice with an equal volume of normal
saline and centrifuged. Urine was collected in successive
portions up to 2, 4, 6, 24h and 2, 3, 4, and 5 days after JM-
40 administration. All samples for platinum analysis were
stored at -25°C. Platinum concentrations in plasma (total
Pt), plasma ultrafiltrate (free Pt), RBCs and urine were
determined for all 28 courses by atomic absorption
spectrometry (AAS) as described before (Vermorken et al.,
1986).
Not all patients were sampled completely. Therefore differ-
ent groups of patients were used to calculate the various
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pharmacokinetic parameters. In 10 courses JM-40 was deter-
mined in plasma ultrafiltrate and urine by high performance
liquid chromatography (HPLC) with UV detection at 214 nm
(Van der Vijgh et al., 1984). Because of the limited stability
of JM-40 in body fluids (Van der Vijgh et al., 1984) all JM-
40 determinations were performed immediately after
collection of the samples. Stability of JM-40 in plasma was
determined by incubating JM-40 in plasma of healthy
volunteers at 37°C for 5 h. The initial concentration was
100pyM. At 0, 0.5, 1, 2, 3 and 5h, samples of lml were
taken, ultrafiltrated, and analyzed for JM-40 as outlined
above.
Pharmacokinetic data analysis
Plasma concentration vs. time curves were fitted to a poly-
exponential equation
n
Cp Yiexp(-1it)
by the computer program NONLIN (Metzler et al., 1974).
Yi-values were corrected for infusion times:
Ci=-AiTYi/(exp(-AiT)-1).
The obtained coefficients Ci and exponents Ai were used to
calculate half-lives, area under the concentration-time curve
(AUC = CI/iA), are under the first moment of the
plasma curve (AUMC = Ci/A), and systemic clearance
(CL=D/AUC, D=dose) (Wagner, 1976). AUC values were
corrected if total Pt levels were not zero at the start of
administration to pretreated patients.
Renal clearance (CLR) was determined from the cumu-
lative urinary excretion (CUE) divided by the AUC both
measured over the same time-interval (6h, including the
infusion time). The AUC 0-6h was calculated by means of
the linear trapezoidal rule. Metabolic clearance (CLM) was
calculated from CL-CLR. Half-life of total Pt over day 1-5
was additionally determined by use of the least squares
method.
The volume of distribution at steady state (V1') of total Pt
was calculated as CL x AUMC/AUC (Wagner, 1976). VI', of
JM-40 and free Pt was calculated according to Collier (1983)
by
Vss
= D(fi MRT1 + f2MRT2)/AUC.
This equation accounts for elimination outside the sampling
(or central) compartment. In this equation
MRT1(=AUMC/AUC) and MRT2(= 1/1 + 1/A2)
are, respectively, the mean residence times in the central and
peripheral compartments, while ft and f2 represent the
fractions of the administered dose eliminated from the
corresponding compartments. These fractions were estimated
from CLR, CLM and the in vitro elimination rate constant of
JM-40 and free Pt in plasma: kivitro. CLR only takes place
from the central compartment, while CLM takes place from
the central compartment (CLM, 1) and the peripheral com-
partment (CLM 2) as well. CLM,l was calculated by CLM,l =
kin vitro X VK in which Vc
=D/E=I C.. The fractions f, and f2
can then be obtained from
ft (CLR + CLM, 1)/CL and f2 (CLM-C41, 1)/CL.
The first order rate constant of metabolic elimination, KM,
represents the overall reactivity of the drug towards body
constituents (plasma as well as tissue components). It was
calculated by analogy with the overall first order rate
constant of elimination at steady state K,,=CL/IV,' (Benet et
al., 1979). Thus: KM =CLM/VSS
Results
Figure 2 shows concentration vs. time curves of JM-40, free
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Figure 2 Semilogarithmic concentration vs. time plots of JM-40
(c), free Pt (x) and total Pt (0) in plasma and Pt in RBCs (A)
after a dose of 786mgm 2 ofJM-40 (patient no. 2, Table I).
Pt and total Pt in plasma as well as Pt in RBCs after
administration of an intermediate dose of JM-40 to a patient
sampled over 45 days. The curves of other patients, followed
for 5 days, had the same appearance as those in Figure 2 up
to day 5. Free Pt concentrations could only be measured
over at least 5 days in patients who received JM-40 at a dose
of 300mgm 2 or higher. JM-40 could be measured over the
first 3.5-7h after infusion of 300-1200mgm-2 (detection
limit of the HPLC assay was 1 tiM). The curves of total Pt
and free Pt over the first 5 days showed a triphasic decline,
while two phases could be observed for JM-40. Plasma levels
of free Pt were higher than that of JM-40, indicating
reaction of JM-40 with low molecular weight endogenous
compounds. The presence of the long lasting third phase of
free Pt is thought to be due to platinum containing break-
down products of protein-JM-40 complexes. A small
temporal rise of the total Pt concentration somewhere
between 3-8h after administration was observed in 10 of the
28 concentration-time curves (36%), suggesting an entero-
hepatic recirculation as has been described for cis-platin
before (Vermorken et al., 1984b, 1986).
Peak concentrations and basic pharmacokinetic para-
meters of JM-40 in individual courses as calculated by
NONLIN are given in Table I. The best number of exponents
as decided by NONLIN was 2 except for patient No. 2,
where the distribution phase could not be distinguished from
the elimination phase. Mean values of common pharmaco-
kinetic parameters are listed in Table II. In general, the
curves of free Pt were best fitted by three exponential
terms, except in the lower dose range (<120 mgm 2)
where the free Pt concentrations were too low to observe
the third phase. The half-life of the third phase of free
Table I Basic pharmacokinetic data of JM-40 in 9 patients (10
courses) as calculated by NONLIN
D T Cpeak C A1 C2 '2
Patient mgm 2 min 1M IM min-1 ,M min-'
lAb 300 12 145 105 0.105 97 0.0151
lBb 364 25 123 128 0.107 93 0.0140
2b,c 786 31 170 - 244 0.0190
3b 800 28 210 169 0.041 131 0.0121
4d 856 92 225 328 0.052 273 0.0136
5 900 55 191 95 0.052 245 0.0168
6 975 60 217 428 0.202 292 0.0173
7b 1,000 52 193 115 0.047 227 0.0176
8 1,000 56 184 280 0.138 217 0.0147
9 1,200 53 250 151 0.078 344 0.0195
D=dose, Cpeak =observed peak concentration. aCorrected for
infusion time; bPreviously treated with spiroplatin or JM-40;
'Creatinine clearance 44mlmin-1; dCreatinine clearance
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Table II Pharmacokinetic parameters (mean+s.d.) after i.v.
infusion of JM-40
JM-40 Free Pt Total Pt
Parametera n=1O n=28 n=28
t1af min 10+5 13+7 13+9
t-I# min 44+7 57+14 60+24
tly days - 3.6+0.8
AUC/D minm21-1 7+2 8+2 210+67
Vc I 11 +3 12+5 12+5
vss 1 17+3 20+6 62+14
CL mlmin- 1 256+ 50 223+47 9+3
CLR mlmin- 1 69+33b 73 +42c
CLM mlmin-1 183+36 154+47
KMx 10- min1 11+2 8+2
aVolumes were normalized to 1.73m2 body surface area; bn
=6; Cn = 18.
Pt (1.9 +0.7 days) was comparable with that of total Pt,
suggesting that this phase represents free Pt released by
degradation of macromolecules reacted with JM-40. All
pharmacokinetic parameters of free Pt were calculated using
the exponents and coefficients of the first two phases only
(Table II). This allowed a comparison of the pharmaco-
kinetics of free platinum originating from JM-40 to those
originating from other platinum compounds, because (a) a
third phase could not be observed for the other compounds
due to either a lower dose or the detection limit of the assay,
(b) kinetic parameters calculated this way refer to probably
comparable species between the compounds. Total Pt
concentration vs. time curves were also best fitted by 3-
exponential equations in most cases. The goodness of fit
parameter r2 (Wagner et al., 1977) ranged from 0.98-0.9999.
Half-lives of free and total Pt (over the first two phases)
were higher than that of JM-40 due to metabolism and
protein binding, respectively. The high standard deviation
observed for t, may be due to the observed increase in half-
life with increasing infusion time. The half-life for total Pt
calculated by means of the least squares method over the
discrete time interval of day 1-5 was 4.1 +0.9 days, being
slightly higher than the value of the terminal half-life calcu-
lated by NONLIN. In figure 2 a fourth phase in the curves
of total Pt and free Pt was observed starting from day 16
onwards. In this patient, half-lives were determined by use of
the least squares method being 15.5d and 14.4d for total Pt
and free Pt, respectively. Linear correlations were observed
between dose m 2 and AUC (P<0.05 for JM-40 (n = 10) and
P<0.01 for free Pt (n=28) and total Pt (n=28)), indicating
linear pharmacokinetics over the dose range studied (20-
1,200mgm 2).
At 6 and 24h after administration protein binding of
platinum was 91 +2 and 93 + 1%, respectively. Due to protein
binding not only in plasma but also in tissues, the systemic
clearance of total Pt was low and the volume of distribution
at steady state was high compared to JM-40 and free Pt.
The volume of distribution and the clearance of free Pt
determined from the first two phases were comparable with
those of JM-40. As expected, the volume of distribution
in the central compartment, VI, was similar for all three
species. The in vitro degradation rate constant of JM-40 in
plasma, kinvitro, was found to be 0.004min-1. For free Pt a
value of 0.002min-1 was determined earlier (Van der Vijgh
et al., 1986). From these values and the mean values of
CLR and CLM the fractions eliminated from the central and
peripheral compartments were calculated to be fi =0.44 and
f2=0.56 for JM-40 and f1=0.43 and f2= 0.57 for free Pt.
V., values calculated with these parameters were about
three times higher for total Pt than for JM-40 and free Pt.
The resultant values of V,, for JM-40 and free Pt listed in
Table II were 17% and 20% higher, respectively, than when
calculated in the conventional way (Wagner, 1976), ignoring
elimination from the peripheral compartment. The metabolic
clearance, CLM, and the overall first order rate constant of
metabolic elimination, KM, were comparable for JM-40 and
free Pt.
Appreciable amounts of JM-40 were excreted in urine. The
cumulative urinary excretion over the first 6h was 27+9%D
(n=5) and 29+13%D (n=19) for JM-40 and free Pt,
respectively. After 24h 42+14% (n=19) and after 5 days
60 + 13% (n = 12) of the administered dose was excreted as
free Pt. The mean values of renal clearance of JM-40 and
free Pt as measured over the first 6h after administration,
were comparable. Both values were similar to the mean
creatinine clearance (71+22, n =23) as measured a day
before the start of therapy. However, individual values of
creatinine clearance and renal clearance of JM-40 (n=5) and
free Pt (n= 10) did not show statistically significant
correlations.
Pt was rapidly taken up by RBCs during the first 20min
of exposure. Maximum levels were reached between 2 and
8h after the start of infusion. The half-life of Pt in RBCs
as measured over day 1-5, was 14+3 days (n= 6). At the
maximum concentration only 0.24+0.12% of the dose
(n=25) was bound to RBCs (Long et al., 1981). Therefore,
platinum uptake by RBCs is not a site of drug accumulation.
Discussion
Our HPLC method (Van der Vijgh et al., 1984) was sensitive
enough to determine JM-40 for at least 5 final half-life times.
Total and free Pt in plasma were determined up to 5 days
following infusion, allowing a reliable fit of a triexponential
equation through the concentation-time curves. A fourth
phase was observed in one patient sampled up to 45 days.
The half-lives of the third and fourth phase of total Pt (4.1
and 15.5 days) were comparable to those of cis-platin (5.3
and 12.0 days) (Vermorken et al., 1984b), suggesting binding
to the same plasma proteins as cis-platin and equivalent
turn-over rates of the Pt-labeled proteins as in the case of
cis-platin.
The pharmacokinetic parameters of free Pt were calculated
with exclusion of the third (and fourth) phase for the
following reasons. Protein binding is regarded as irreversible
(Repta et al., 1980). Therefore, the long terminal phase of
free Pt and the parallelism of the fourth phase of free Pt
with that of total Pt (Figure 2) suggests that the third phase
of the free Pt curves (if detectable) represents platinum
containing degradation products of high molecular weight
compounds (i.e. proteins and tissue components) (King et
al., 1986). Since protein bound platinum has no toxic or
antitumour activity (Repta et al., 1980) this will probably
also hold for the platinum containing degradation products
of those proteins. Besides, pharmacokinetic parameters of
free Pt calculated without taking into consideration an
eventually present third phase allows intercomparison of free
platinum species originating from most platinum compounds
for which it was not possible to detect a third phase.
Therefore, we decided to omit these secondary free platinum
species from the calculation of clearance and volume para-
meters by using only the first two phases, mainly referring to
JM-40 and its low molecular weight metabolites. The
pharmacokinetic parameters of free Pt were similar to those
of JM-40. This similarity suggests that the formation of low
molecular weight (<30,000 dalton) metabolites accounts for
only a small part of the total metabolic elimination of JM-40.
The major part of metabolic elimination of platinum
compounds is due to irreversible ligand exchange reactions.
It is very likely that this takes place not only in the central
compartment but also in the peripheral compartments
(lumped together as compartment 2). This was taken into
account by the way VSS was calculated (Collier, 1983).
Accurate estimation of VSS was desirable, because it was used
to calculate KM. The rate constants KM of JM-40 and free Pt
were lower than that of free Pt after administration of cis-482 F. ELFERINK et al.
platin (15x10-3min-1) due to a lower CLM and a com-
parable VI' (Vermorken et al., 1984b, 1986; Elferink et al.,
submitted). The lower value of CLM is in agreement with the
lower values of (a) the in vitro rate constants of plasma
protein binding (0.0020 vs. 0.0068min-1 (Van der Vijgh et
al., 1986)) and (b) degradation of the intact drugs in plasma
(0.0040min-1, this study vs. 0.0077min-1 (Repta et al.,
1980)) compared to cis-platin, respectively. The difference in
CLM is also reflected by the difference in tissue binding (%
D) as observed in animals (Boven et al., 1985; Van der Vijgh
et al., 1983) being 2 to 4 times higher for cis-platin than for
JM-40.
As mentioned before, platinum complexes like cis-platin
(Vermorken et al., 1984b, 1986) or carboplatin (Elferink et
al., submitted; Harland et al., 1984) did not show a third
phase in the free Pt vs. time curves. Probably a third phase
of free Pt is also present after administration of cis-platin
and carboplatin, but with concentrations of secondary free
Pt below the usual limit of detection, due to a lower dose
(cis-platin) or a smaller rate constant of protein binding
(carboplatin) (Van der Vijgh et al., 1986). Indeed, very
recently one study reported a very long terminal phase for
free Pt following administration of cis-platin, determined
with a very sensitive assay for free Pt (Reece et al., 1986).
Half-lives of free Pt were lower after cis-platin than after
JM-40. This is principally due to the higher protein binding
of cis-platin compared to JM-40, which is also reflected by a
lower CUE of platinum after cis-platin than after JM-40.
Since the urinary excretion of proteins is generally very
limited excreted Pt may be regarded as free Pt. Renal
clearance of free Pt after administration of JM-40 was
similar to that after cis-platin (Vermorken et al., 1986).
Therefore, the higher cumulative urinary excretion of free Pt
after JM-40 compared to that after cis-platin (CUEO-6h=
24+5%D (Vermorken et al., 1984b), CUEO_24h=28+4%D
(Vermorken et al., 1986) is due to the lower rate of reaction
with proteins after JM-40.
KM of JM-40 was higher than that of carboplatin
(diammine(1,l-cyclobutanedicarboxylato)platinum(II), KM =
1.5 x 10-3min- 1 for free Pt) (Elferink et al., submitted),
which is in agreement with the difference of their in vitro
reaction rates with plasma proteins (Van der Vijgh et al.,
1986; Harland et al., 1984). This means that the in vivo
reactivity of JM-40 is higher than that of carboplatin,
although they are structurally closely related. X-ray structure
analysis revealed, however, that the geometry around the
platinum atom of JM-40 shows more deviations from bond
angle ideality than that of carboplatin (Cutbush et al., 1983;
Neidle et al., 1980). Furthermore, the cyclobutane group of
carboplatin may sterically hinder nucleophilic attack of the
platinum atom (Neidle et al., 1980). These facts may explain
the higher reactivity of JM-40 compared to carboplatin, and
also why, from a pharmacokinetic point of view, JM-40
seems to be more related to cis-platin than to carboplatin
(Vermorken et al., 1984b, 1986; Elferink et al., submitted;
Harland et al., 1984). Besides, the dose-limiting toxicities of
JM-40 (nephro and gastro-intestinal toxicity, (Winograd et
al., 1986)) are similar to that of cis-platin, whereas the dose
limiting toxicity of carboplatin is myelotoxicity (Joss et al.,
1984). Vermorken et al. (1985) indicated a relationship
between the nephrotoxic properties of 6 platinum complexes
and their stability in aqueous solution. Therefore, the inter-
mediate in vivo reactivity of JM-40 may account for its dose
limiting nephrotoxicity (in contrast to carboplatin), but at a
much higher dose than cis-platin.
JM-40 was not entered into phase II trials because of its
toxicity profile. Nevertheless, JM-40 has contributed to a
better understanding of possible relationships between
chemical, pharmacokinetic and clinical properties of
platinum compounds.
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